| Dr Joni R Summitt, DO | |
|
1140 E Michigan Ave Ste 400, Lansing, MI 48912-1806 | |
| (517) 364-9650 | |
| (517) 364-9605 |
| Full Name | Dr Joni R Summitt |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 1140 E Michigan Ave Ste 400, Lansing, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588662373 | NPI | - | NPPES |
| 2620749 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 5101008210 (Michigan) | Primary |
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831139088 PECOS PAC ID: 6709799166 Enrollment ID: O20040102000790 |
News Archive
A pioneering new study is set to help surgeons repair hearts without damaging precious tissue. A team of scientists from Liverpool John Moores University, The University of Manchester, Aarhus University and Newcastle University, have developed a way of producing 3D data to show the cardiac conduction system - the special cells that enable our hearts to beat - in unprecedented detail.
Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.
The Venza Group's Instructional Designers worked closely with client-side subject matter experts to create the eGuides, and the industry-leading Venza eGuide rapid development tool was used to build them. In the end, 69 eGuides totaling 571 screens and 1,071 steps were generated. The overall project was completed in a timely manner to the complete satisfaction of all concerned.
Demyelinating diseases, such as multiple sclerosis (MS), are frequently associated with the progressive loss of vision. The retinal nerve damage is thought to be caused by immune system-mediated inflammation; however, other demyelinating disorders, such as Pelizaeus-Merzbacher disease, do not involve the immune system, suggesting that there are other causes of retinal nerve damage.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joni R Summitt, DO Po Box 13008, Lansing, MI 48901-3008 Ph: (517) 364-9650 | Dr Joni R Summitt, DO 1140 E Michigan Ave Ste 400, Lansing, MI 48912-1806 Ph: (517) 364-9650 |
News Archive
A pioneering new study is set to help surgeons repair hearts without damaging precious tissue. A team of scientists from Liverpool John Moores University, The University of Manchester, Aarhus University and Newcastle University, have developed a way of producing 3D data to show the cardiac conduction system - the special cells that enable our hearts to beat - in unprecedented detail.
Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.
The Venza Group's Instructional Designers worked closely with client-side subject matter experts to create the eGuides, and the industry-leading Venza eGuide rapid development tool was used to build them. In the end, 69 eGuides totaling 571 screens and 1,071 steps were generated. The overall project was completed in a timely manner to the complete satisfaction of all concerned.
Demyelinating diseases, such as multiple sclerosis (MS), are frequently associated with the progressive loss of vision. The retinal nerve damage is thought to be caused by immune system-mediated inflammation; however, other demyelinating disorders, such as Pelizaeus-Merzbacher disease, do not involve the immune system, suggesting that there are other causes of retinal nerve damage.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 2 days ago
Aline De Quadros Teixeira, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1200 E Michigan Ave Ste 500, Lansing, MI 48912 Phone: 517-364-5184 | |
Dr. Harry James Mccoy, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Ali H. Sheikh, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 517-364-9650 Fax: 517-364-9605 | |
Georgette Nader, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-253-8366 | |
Salma Mohamed, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-1000 | |
Dr. Cynthia S. Boynton, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Fadi Mohammadsaeed S Alreefi, M.D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 419-921-2531 Fax: 517-364-9605 |